HSCT

CRISPR-Cas9 presents new possibilities for Thalassemia treatment.

The autosomal recessive inherited blood disorder, b-thalassemia, is caused by reduced or absent synthesis of the beta chains of hemoglobin due to mutations within the HBB gene. The severity of the disease depends on the nature of the mutation and whether the mutations are present in heterozygous or homozygous form. Another autosomal recessive inherited hemoglobinopathy …

CRISPR-Cas9 presents new possibilities for Thalassemia treatment. Read More »

Devyser launches first NGS-based test for mixed chimerism

Swedish molecular diagnostics company Devyser, announced today at the 45th annual European Bone Marrow Transplantation (EBMT) meeting in Frankfurt, Germany, the release of a new NGS-based assay for ultrasensitive and precise measurement of mixed chimerism after Human Stem Cell Transplantation. At EBMT, Devyser presented data obtained with the new Devyser Chimerism assay generated in collaboration …

Devyser launches first NGS-based test for mixed chimerism Read More »